Business Context and Reporting Period
This Form 8-K filing by Natera, Inc. (NTRA) was submitted on April 13, 2020. The report discloses preliminary financial results for the fiscal quarter ended March 31, 2020, and addresses significant operational impacts resulting from the COVID-19 pandemic. The company operates in the genetic testing sector, with a significant portion of revenue concentrated in the United States.
Key Financial Metrics
- Revenue: Estimated total revenues for the three months ended March 31, 2020, range from $89 million to $91 million.
- Profitability: The company expects an operating loss for the quarter generally consistent with the prior quarter. Specific loss figures are not provided in this filing.
- Operational Volume: Approximately 235,000 tests were processed during the quarter.
- Debt and Liquidity: The filing does not provide specific cash flow, debt, or liquidity metrics for the quarter. However, the company announced an intention to offer $250 million in aggregate principal amount of convertible senior notes due 2027, with an option for purchasers to acquire an additional $37.5 million.
Material Changes and Developments
Test volumes began to decrease in the second half of March 2020 due to the spread of COVID-19 and subsequent limitations on the U.S. healthcare system. Many customers, including hospitals and clinics, suspended non-emergency appointments, leading to a significant decrease in test volume. The company anticipates that test volumes will continue to be adversely affected and cannot predict when volumes will return to normal.
Guidance, Outlook, and Risks
- Guidance Withdrawal: Due to the unknown duration and extent of the pandemic's impact, Natera is withdrawing its previously announced guidance for 2020. Estimates regarding target market sizes may also change materially.
- Outlook: Management expects a material adverse impact on financial results for at least the next quarter and potentially the full year, depending on the timing of the lifting of healthcare limitations and economic recovery.
- Risks: Key risks include government-imposed shelter-in-place orders affecting employees and operations, supply chain disruptions for laboratory reagents, difficulties in recruiting clinical trial participants, and potential payment delays from third-party payers. The company also faces risks related to the discretionary nature of certain products (e.g., IVF market) in a recessionary environment.
- Unusual Items: The filing highlights the unprecedented nature of the pandemic, noting there are no comparable recent events to guide the ultimate impact on the business.
Investor Verification Checklist
- Verify the final audited financial results for the quarter ended March 31, 2020, once the official 10-Q is filed, as current figures are preliminary estimates.
- Monitor the status and closing details of the proposed $250 million convertible senior notes offering.
- Track weekly or monthly test volume trends to assess the severity and duration of the COVID-19 impact on operations.
- Review updates on third-party payer reimbursement policies and payment cycles in the context of the pandemic.
- Assess the company's ability to maintain laboratory operations and supply chain continuity under ongoing government restrictions.